Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Home hemodialysis (HHD) remains a relatively novel modality in the Middle East, often adopted not as a first-line therapy but as a transition from in-center hemodialysis (ICHD) when continued in-center care becomes unfeasible due to debilitating conditions such as stroke, fractures, or dementia. In such cases, the need for home nursing support may offset the cost advantages associated with HHD observed in other settings. This study describes patient- and service-level characteristics and clinical outcomes during the first two years of the DaVita-JHAH Saudi HHD program.
We conducted a retrospective analysis of patients with kidney failure who initiated HHD between June 2022 and March 2025 in the DaVita-JHAH program. Variables assessed included demographic data, comorbidity burden, vascular access type, hospitalization frequency, and one-year all-cause mortality.
A total of 118 patients were included (mean age 70.8 ± 11.6 years; 46.6% female). Of these, 72.0% used conventional HHD machines, and 28.0% used NxStage systems. Arteriovenous fistula or graft was used in 54.2% of cases. The median dialysis vintage before HHD initiation was 14.8 months (IQR: 3.0–48.1). Diabetes (71.2%), hypertension (10.2%), and chronic glomerulonephritis (4.2%) were the most common causes of kidney failure. A Charlson Comorbidity Index ≥2 was present in 93.2% of patients, with notable rates of heart failure (31.4%), myocardial infarction (30.5%), stroke (13.6%), and peripheral vascular disease (10.2%). The one-year all-cause mortality rate was 14.7% (95% CI: 6.7%–22.7%), corresponding to approximately 7.0 deaths per 100 patient-years. The hospitalization rate was 4.3 events per 1000 patient-days of follow-up.
All-cause mortality among HHD patients in this cohort was relatively high, likely reflecting the substantial burden of comorbid conditions within this population.
